|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
57,680,000 |
Market
Cap: |
1.71(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$14.05 - $32.15 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Protagonist Therapeutics is a clinical-stage biopharmaceutical company with various peptide-based new chemical entities in different stages of development, all derived from Co.'s proprietary technology platform. Co.'s clinical programs address two main categories of diseases; hematology and blood disorders, and inflammatory and immunomodulatory diseases. Co.'s main clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 specific integrin antagonist for inflammatory bowel disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
93,396 |
175,244 |
175,244 |
175,244 |
Total Sell Value |
$2,858,339 |
$4,519,351 |
$4,519,351 |
$4,519,351 |
Total People Sold |
3 |
5 |
5 |
5 |
Total Sell Transactions |
6 |
9 |
9 |
9 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Patel Dinesh V Ph D |
President and CEO |
|
2017-05-09 |
4 |
OE |
$1.16 |
$22,155 |
D/D |
19,099 |
190,437 |
|
- |
|
Patel Dinesh V Ph D |
President and CEO |
|
2017-04-06 |
4 |
OE |
$1.16 |
$23,200 |
D/D |
20,000 |
171,338 |
|
- |
|
Patel Dinesh V Ph D |
President and CEO |
|
2017-03-10 |
4 |
OE |
$0.87 |
$14,235 |
D/D |
16,362 |
151,338 |
|
- |
|
Patel Dinesh V Ph D |
President and CEO |
|
2016-12-22 |
5 |
OE |
$0.87 |
$2,610 |
D/D |
3,000 |
134,976 |
|
- |
|
Johnson & Johnson Development Corp Et Al |
10% Owner |
|
2016-08-16 |
4 |
B |
$12.00 |
$6,999,996 |
I/I |
583,333 |
2,449,183 |
1.5 |
- |
|
Johnson & Johnson Development Corp Et Al |
10% Owner |
|
2016-08-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,865,850 |
1,865,850 |
|
- |
|
Papanek Julie |
Director |
|
2016-08-16 |
4 |
B |
$12.00 |
$6,999,996 |
I/I |
583,333 |
2,453,255 |
2.1 |
- |
|
Papanek Julie |
Director |
|
2016-08-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,869,922 |
1,869,922 |
|
- |
|
Canaan Partners X Llc |
Director |
|
2016-08-16 |
4 |
B |
$12.00 |
$6,999,996 |
D/D |
583,333 |
2,453,255 |
3.92 |
- |
|
Canaan Partners X Llc |
Director |
|
2016-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,869,922 |
1,869,922 |
|
- |
|
Hall Steven Edward |
10% Owner |
|
2016-08-16 |
4 |
B |
$12.00 |
$6,999,996 |
I/I |
583,333 |
2,099,482 |
1.5 |
- |
|
Hall Steven Edward |
10% Owner |
|
2016-08-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,516,149 |
1,516,149 |
|
- |
|
Shanafelt Armen |
Director |
|
2016-08-16 |
4 |
B |
$12.00 |
$6,999,996 |
I/I |
583,333 |
2,099,482 |
2.25 |
- |
|
Shanafelt Armen |
Director |
|
2016-08-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,516,149 |
1,516,149 |
|
- |
|
Hodder William A |
Sr. VP - Corporate Development |
|
2016-08-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,943 |
|
- |
|
Patel Dinesh V Ph D |
President and CEOOfficer |
|
2016-08-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
131,976 |
|
- |
|
166 Records found
|
|
Page 7 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|